2020 American Transplant Congress

Saturday, May 30, 2020

3:27pm-3:39pm

Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, N. Tanimine¹, H. Tahara¹, K. Ide¹, T. Kobayashi¹, Y. Tanaka¹, A. Tzakis², S. Nishida², H. Ohdan¹

Liver: Hepatocellular Carcinoma and Other Malignancies II  •  Virtual

3:27pm-3:39pm

Altruistic Liver Donors at Thomas E Starzl Transplant Institute: Impact of the Educational Campaign: Gift of Life

S. Ganesh, M. Molinari, L. Tubb, A. Tevar, C. Hughes, J. Behari, A. Humar

Liver: Living Donors and Partial Grafts I  •  Virtual

3:27pm-3:39pm

An Optimized Integrative Model Using Urinary Chemokines for Noninvasive Diagnosis of Acute Allograft Rejection

C. Tinel¹, A. Devresse¹, A. Vermorel¹, D. Marx², S. Caillard², C. Legendre¹, M. Rabant³, D. Anglicheau¹

Biomarkers, Immune Assessment and Clinical Outcomes I  •  Virtual

3:27pm-3:39pm

Anticipated Cost Savings of Using Lungs from Hepatitis C-Positive Lung Donors for Hepatitis C-Negative Recipients

K. Ryland¹, J. Mallea², J. Moriarty³, L. White⁴, B. Borah⁵, J. Naessens³

Lung: Let's Start at the Beginning: Pre-Transplant Decision Making and Access to Lung Donors  •  Virtual

3:27pm-3:39pm

Assessing Interventions to Improve Patient Care Conducted by Pharmacists at an Outpatient Renal Transplant Clinic within a Collaborative Pharmacy Practice Agreement

K. Johnson, R. Chelewski, A. Langone, M. Peter, A. Zuckerman

Quality Assurance Process Improvement & Regulatory Issues I  •  Virtual

3:27pm-3:39pm

Causes of Kidney Allograft Loss (GL) in the Current Era of Donor-Specific Alloantibody (DSA) Testing

M. Merzkani¹, X. Benavides¹, M. D'Costa¹, B. Smith¹, W. Park¹, A. Rule¹, H. Chakkera², K. Reddy², M. Alexander¹, H. Amer¹, M. El Ters¹, C. Schinstock¹, R. Heilman², A. Bentall¹, M. Stegall¹

Kidney Complications: Immune Mediated Late Graft Failure  •  Virtual

3:27pm-3:39pm

Change in the Willingness of Transplant Candidates to Accept Hepatitis C Virus Positive Deceased Donor Organs in the Era of Direct-Acting Antivirals

Q. Yuan, S. Hong, E. Roth, M. Sise, E. Bethea, W. Williams, H. Yeh, N. Elias

All Organs: Viral Hepatitis  •  Virtual

3:27pm-3:39pm

Characterizing the Waitlist Candidate Who Was Bypassed by the Successfully Transplanted Candidate with Alcoholic Hepatitis

J. Ge¹, C. L. Berg², F. Y. Yao¹, J. P. Roberts³, J. C. Lai¹

Liver: MELD, Allocation and Donor Issues (DCD/ECD) I  •  Virtual

3:27pm-3:39pm

Clinical Outcomes from a Mobile Health, Pharmacist-Led Intervention: 12-Month Results of the Transafe Rx Randomized Controlled Trial

D. Taber, J. Hirsch, Z. Su, J. McGillicuddy, A. Posadas, J. Fleming

Late Breaking Oral Abstract  •  Virtual

3:27pm-3:39pm

Co-Stimulatory Blockade Immunosuppression Facilitates Lung Allograft Acceptance Through an Increase in Local IL-5 Production by Type 2 Innate Lymphoid Cells

Y. Guo, Z. Mei, A. Hata, B. Mahgoub, D. Li, A. Manafi, A. Banerjee, A. Gelman, D. Kreisel, A. Krupnick

Innate Immunity; Chemokines, Cytokines, Complement  •  Virtual